
Pharmacosmos’ PHOSPHARE study program demonstrates a safety advantage of iron isomaltoside
Pharmacosmos announces the first results of the PHOSPHARE study program in which iron isomaltoside was compared directly to ferric carboxymaltose in two identical randomized controlled trials. Iron isomaltoside 1000 and ferric carboxymaltose are intravenous iron preparations that can be administered in high doses to